V12 SENTINEL ENGINE · AI MARKET ANALYSIS
Mid
A
AZNAI Stock Diagnostic Report

AstraZeneca submits NDA for savolitinib + Tagrisso for NSCLC

AstraZeneca has submitted a new drug application (NDA) for the combination therapy of selpercatinib and Tagrisso for non‑small cell lung cancer, raising expectations for regulatory progress.

View Source Article ↗
AI CATALYST SCORE60 / 100Score computed by Sentinel V12
REFERENCE PRICENot measuredReference entry price at analysis time
+
ANALYSIS HISTORY

AZN Analysis History (Last 30 Days)

Diagnosed AtTickerAI ScoreTier
2026-09-29 17:35:33AZN60MidView Report →
2026-09-29 08:25:56AZN65MidView Report →
2026-09-29 01:44:11AZN60MidView Report →
View Full History for AZN (Blueprint) →